The Pharma Letter1h
Ligand invests $75 million in Castle Creek’s gene therapy
Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...
BioSpace1h
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
ENDPOINTS NEWS19h
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
FierceBiotech22h
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
Le Lézard1d
Board-Certified Physicians Celia Garner, MD, and Nicholas G. Hanson, MD, Open MDVIP-Affiliated Practices in Salt Lake City
MDVIP, the market leader in membership-based healthcare with a network of over 1,300 primary care physicians nationwide, has ...
Le Lézard1d
Cision and PRWeek Unveil 2025 Comms Report: AI Adoption Accelerates as Communications Leaders Gain Greater Influence in the C-Suite
Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...